GSK responds to the AMR Benchmark

Issued: London, UK

Responding to the publication of the first-ever Antimicrobial Resistance (AMR) Benchmark, published today by the Access to Medicines Foundation, Phil Thomson, President, Global Affairs, at GSK said:

“The new AMR Benchmark provides a useful analysis of the industry’s contribution to addressing the severe public health threat of antimicrobial resistance.  We are pleased that our contribution has been positively recognised.  But the scale of the task ahead remains acute.  Specifically for the pharmaceutical industry, we need to find creative ways to incentivise and reward new research and development in antibiotics. All parts of society must come together to tackle this issue.”

The AMR Benchmark complements the recent report from the AMR Industry Alliance, measuring the progress of the pharmaceutical industry in response to public commitments stated in the Industry Davos Declaration and AMR Roadmap in 2016.  Also expected shortly is the publication of recommendations from the DRIVE-AB consortium, calling for new incentives to stimulate antibiotic innovation along with provisions for sustainable use and access.

GSK - a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For more information, visit about us.